23^rd International Conference on
Cancer Research & Pharmacology

Hiroshi Kobayashi received his Ph.D. in Biochemistry from University of Tokyo in 1974. After his postdoctoral training at Colorado University Medical Center, he started to study adaptation strategies of microorganisms to acidic environments at Chiba University in 1978. His research has been focused on mammalian cell functions under acidic conditions from 1996 at Graduate School of Pharmaceutical Sciences, Chiba University. His current challenge is to develop cancer chemotherapy specific to acidic nests. He retired in March 2012 and is now a professor emeritus at Chiba University. He works as an associate editor of International Immunopharmacology published by Elsevier B.V. from 2014.

cancer chemotherapy

William T. Beck, PhD, is University Distinguished Professor and former Head of the Department of Biopharmaceutical Sciences in the College of Pharmacy at the University of Illinois at Chicago. His research efforts have focused on understanding the molecular and genetic mechanisms of anticancer drug action and tumor cell resistance to anticancer drugs. His current research focuses on splicing factor genes and their involvement in cancer initiation, progression, and resistance to therapy, as well as their potential as novel therapeutic targets in ovarian, breast, and brain cancers.

cancer initiation, progression, and resistance to therapy

Shalini Gupta is the Associate Professor, Department of Oral Pathology & Microbiology, King Georges Medical University, Lucknow, India. She had University Merit Scholarship and got fourteen Gold Medals. She has involved with various research projects & reviewer in various journals. She has written two books and published around 50 papers in reputed journals and serving as an editorial member of many reputed journals

Clinical Trials Operations, Risk Based Monitoring, Medical Writing, PVG

Antonio Gómez-Muñoz received his Ph.D in Biochemistry from the University of the Basque Country, Bilbao (Spain) in 1988. He achieved postdoctoral training at the University of Alberta in Edmonton (Canada) from 1988 to 1994. He then accepted a Research position at the Spanish Research Council (CSIC) from 1995 to 1996. From 1997 to 1998, he worked as Research Associate at the University of British Columbia (Vancouver, Canada). Since then, he has been working at the University of the Basque Country in Bilbao (Spain), where he is currently Professor of Biochemistry and Molecular Biology. He belongs to the Editorial Advisory Board of various scientific journals. Since 2001, he is a member of the International Advisory Committee of the Charleston Ceramide Conference, and since 2005, he is permanent Co-chair of the European Sphingolipid Club. His research interest is on the regulation of lipid metabolism and signalling, and in recent years he focused on the targeting of sphingolipid metabolites and enzymes with the aim of developing new strategies for prevention of disease.

Biochemistry, Molecular Biology, Oncology

Barbara DeVivo has spent her entire career in marketing management serving various executive global roles from market analysis and research, business development product management and professional relations. Ms. DeVivo has also amassed a strong proficiency in all facets of marketing management, sharing both academic and professional experiences. Currently, Ms. DeVivo is a PhD student at the State University of New York at Albany- Rockefeller College of Public Affairs and Policy whose research is centered on Organizational Behavior Management in Healthcare. Additionally, she serves as President and Founder of Extended Marketing Services, a real estate and healthcare consulting company. Ms. DeVivo has also held the position of Adjunct Professor of Marketing at the University of Memphis as well as Union Graduate College and has taught Marketing, Advertising and Brand Promotions, Market Research, and Negotiations. Furthermore, she has held the position of Executive Director of Marketing at the University of Memphis managing the operations, strategy development and execution of all marketing activities for its business school. Prior to then, Ms. DeVivo served in the healthcare industry as Director of Professional Relations for Thermage and was responsible for managing the key physician opinion leaders for the company world-wide and creating global awareness of all clinical and professional activities conducted by physicians and the company. From 2005-2007, she served as Director of Marketing for RITA Medical where she lead the company’s drug eluting therapy efforts in the oncology market for the treatment of nonresectable metastatic liver, lung and kidney tumors, broke through and built the US market with a novel procedure and served the company through product management, business development and market analysis for emerging businesses. Prior to RITA, Ms. DeVivo worked for CR Bard managing the company’s brachytherapy oncology business for the treatment of prostate and breast cancer.

Healthcare Management and Organizational Management

Michael Retsky (Ph.D in physics from University of Chicago) made a career change from physics to cancer research. He is Editor-in-Chief of Journal of Bioavailability and Bioequivalence, on staff at Harvard School of Public Health, honorary faculty at University College London, and Prof Adj at UANL, Monterrey, Mexico. He was on Judah Folkman’s staff at Harvard Medical School for 12 years. He is on the board of directors of the Colon Cancer Alliance and has published more than 60 papers in physics and cancer. He has a patent pending for treatment of early stage cancer.

Cancer research, charged particle optics, early detection of cancer and delayed detection of cancer.

Yoshiaki Omura received both Oncology Residency Training and a Doctor of Science Degree through research on Pharmaco-Electro Physiology of Single Cardiac Cells in vivo and in vitro from Columbia University. He has published over 250 articles and 7 books. He is Executive Editor of Integrative Oncology & Editorial Board Member of Journal of Clinical Trials in Cardiology, etc. Using his new diagnostic method, which received U.S. patent, he can non-invasively and rapidly measure many neurotransmitters, other chemicals, asbestos, viruses, and bacteria. He developed non-invasive quick diagnostic methods of malignancies, as well as a method of evaluating the effects of any treatment.

Acupunture & Electro-Therapeutics Research, Integrative Oncology

Dr. Sell is a board certified pathologist and immunologist. He has published over 400 papers and 12 books. His paper with Barry Pierce (Lab. Invest. 70:6-21, 1994.) was selected as an AACR scientific landmark. Among his findings are: development of delayed hypersensitivity before antibody formation (1959). the role of the thymus in development of immune competence (1964); first identification of immunoglobulin on the surface of B cells (1965; Current contents citation classic, 1984); classification of immunopathological reactions (1971); development of a radioimmunoassay for alphafetoprotein (1972); identification of liver stem cells during chemical hepatocarcinogenesis and in response to injury (1972-94); role of endocytosis in activation of B cells (1974); recognition that the chancre of syphilis is a delayed hypersensitivity reaction (1979); role of mGSTA3 in detoxification of aflatoxin (2004); and characterization of breast cancer stem cells (2012).

Cancer: To determine how bone marrow derived mesenchymal stem cells influence the development of cancers in other tissues. Cancer: To block proliferation of breast cancer stem cells by small molecular inhibitors or inhibitory RNA. This is a critical step to preventing re-growth of breast cancer after chemotherapy or radiation therapy. Carcinogenesis: To study the metabolism of aflatoxin and development of liver cancer in mice lacking glutathionine-S-transferase. Aging: To compare the ability of young vs. old bone marrow derived stem cells to reconstitute and provide long term survival after lethal irradiation and transplantation, and the ability of wild-type bone marrow to prolong life of early aging mice.

Homer S. Black is a Professor of Dermatology, Baylor College of Medicine, Houston, Texas (1968- 2003).He is a Research Physiologist and Director of the Photobiology Laboratory at the Veterans Affairs Medical Center in Houston. Dr. Black earned a Ph.D. in biochemistry from Louisiana State University in 1964. He earned a B.Sc. in animal science from Texas A&M University in 1956 after which he served with the U.S. Air Force in Strategic Air Command and holds a M.Ed. from Sam Houston State University; and a M.S.Admin. (business/health science management) from the University of Houston. He was a Senior Fulbright Scholar at the Photobiology Centre, University of Dundee, Scotland. . He served as Treasurer in the latter. Dr. Black is also a member of the Institute of Professional Managers and was Chairman of the Board of Regents for the Academy of Administrative Managers.

Pro-carcinogenic effects of antioxidants and dietary fat in UV-carcinogenesis. The experimental studies culminated in a dietary intervention trial in which it was shown that a low-fat dietary intervention reduced the risk for subsequent skin cancers in skin cancer patients.

The central theme of Gary Stein’s research has been to discover mechanisms controlling proliferation and differentiation emphasizing compromised regulation linked with disease. His lab characterizes transcriptional regulation that mediates cell cycle control, focusing on molecular mechanisms regulating gene expression at the G1/S phase transition in normal and tumor cells and the abbreviated pluripotent cell cycle in human embryonic stem cells. He has a major commitment to investigating bone tissue specific gene expression, including microRNA-mediated control, within the context of skeletal development and bone remodeling as well as aberrations that accompany the onset and progression of skeletal disease. The Stein lab is defining functional relationships between the subnuclear organization of regulatory proteins and gene expression, pursuing mechanisms that support combinatorial organization and assembly of regulatory machinery in nuclear microenvironments and epigenetic control of cell fate and lineage commitment in biological control and cancer.

--

Bradford has a PhD in Medical Biochemistry-Oncology from the Roswell Park Cancer Institute, Division of SUNY at Buffalo School of Medical and Biomedical Sciences. She is the inventor of the various patents that AccuTheranostics holds. She was awarded the Award for Excellence in Research from the American Federation for Clinical Research, has authored many scientific papers and book chapters, and been an invited speaker at various international scientific meetings. Dr. Bradford is a member of many major professional cancer organizations including, ASCO, AACR and AAAS. As Chief Scientific Officer, Dr. Bradford guides the day-to-day research directives as well as the clinical laboratory operations.

--

Dr. Phillips is a national leader in the treatment of hematologic malignancies and is an innovator in bringing transplant modalities to lymphoma. He is a graduate of the University of Oklahoma School of Medicine where he completed his internship in internal medicine. He continued his residency training at the University of North Carlina School of Medicine and trained at Washington University School of Medicine with a clinical and research fellowship in hematology/oncology. He previously directed the transplant programs at the University of Maryland, University of Kentucky, theUniversity of British Columbia, and Barnes Hospital at the Washington University School of Medicine. Dr. Phillips was the principal investigator of the National Cancer Institute (NCI) study "Improving the Ability of (High-Risk) Hematologic Malignancy Patients to Undergo Allogenic Stem Cell Transplantation".

Hematologic malignancies, Allogenic Stem Cell Transplantation,Internal medicine,Lymphoma.

Kandace Williams is a Professor in the Department of Biochemistry, Cancer Biology at the University of Toledo College of Medicine since 2001. She was formerly a faculty member at the University of Alaska Biomedical Program. Her postdoctoral fellowship was with Dr. Lawrence Loeb in the Department of Pathology at the University of Washington School of Medicine. She is currently affiliate faculty in the Department of Pathology. She received her PhD from the Department of Pharmacology and Toxicology at Dartmouth Medical School and her BS Cum Laude at the University of Alaska Anchorage. She has served on the NIH Cancer Etiology and Chemical Pathology study sections for several years is on the Editorial Board of Mutation Research and a Board member of American Society for Circumpolar Health as well as Council member of the Environmental Mutagen Society. She also serves in the UTCOM Institutional Review Board for Human Research Cancer Biology PhD Program, Steering Committee Cancer Center Program, Director of Cell Biology and Pathogenesis section.

Mechanisms of DNA damage and repair of alkylating agents.Base excision and mismatch repair within different phases of the cell cycle. Mismatch repair-induced DNA damage response and cell cycle effects.DNA damage response effects on replication factories.

Dental School University of Medicine and Dentistry of New Jersey 110 Bergen Street Newark

Oral Biology

Mitchell Ho is an Investigator and Head of the Antibody Therapy Unit in the Laboratory of Molecular Biology at the National Cancer Institute (NCI). Dr. Ho received his Ph.D. from the University of Illinois at Urbana-Champaign, where he studied monoclonal antibodies for the treatment of cocaine addiction as a National Research Service Award Fellow with Mariangela Segre. He completed postdoctoral studies with Ira Pastan at the NCI working on immunotoxin therapy of cancer. Research in Dr. Ho’s laboratory studies mesothelin, CA125/MUC16 and other cell adhesion molecules as therapeutic targets in order to develop novel antibodies and immunoconjugates to treat ovarian cancer, mesothelioma and liver cancer. He has developed the mammalian cell display method which is currently being used by investigators worldwide to identify and engineer therapeutic antibodies. Dr. Ho is a recipient of Mesothelioma Applied Research Foundation Award, and Ovarian Cancer Research Fund Individual Investigator Award.

Ovarian cancer, liver cancer

Frederick Domann is a Professor of Radiation Oncology in the Free Radical Radiation Biology Program at The University of Iowa in Iowa, USA . He earned his PhD from the University of Wisconsin, Madison in Human Cancer Biology under the mentorship of Kelly H Clifton and subsequently carried out postdoctoral research at The Arizona Cancer Center with G Tim Bowden. He joined the faculty at The University of Iowa in 1993 and has become an internationally recognized expert in and free radical biology and cancer.

Transcriptional regulation ,Free radical biology ,Metabolism ,Epigenetic control of gene expression in human cancer

Demir Akin Congretionally Directed Medical Research Programs, Breast Cancer Research Program, National Cancer Institute, Alliance for Nanotechnology in Cancer, Radiation Oncology Program, CDMRP/DoD, American Association for Cancer Research (AACR), U.S. Civilian Research and Development Foundation (CRDF).

Biological Engineering and Micro/Nanomedicine, Genomics/Systems Biology, Gene Therapy/Microbiology/Virology.

Liang Xu is an Associate Professor in the Department of Molecular Biosciences at University of Kansas

Molecular therapy targeting cancer and cancer stem cells, cancer biology, drug discovery and drug/gene delivery. Funded by multiple NIH and DOD grants, his lab is working on molecularly targeted cancer therapy and chemo/radiosensitization by modulating cell death signaling pathways, autophagy and apoptosis. We are exploring microRNAs as novel targets for cancer and cancer stem cells. Novel nanotechnology to develop nanovectors targeting cancer stem cells and exploring novel molecular therapy for cancer stem cells.

Dr. Jimmy Efird is an Associate Member of the Leo Jenkins Cancer at Brody School of Medicine. Additionally, he holds a joint appointment as Associate Professor in the Department of Public Health and as Epidemiologist/Chief Statistician (Director, Shared Resources) in the Center for Health Disparities. Dr. Efird received his Ph.D. from Stanford University (Epidemiology with a concentration in Biostatistics). His expertise includes statistical methods for assessing gene-environment interaction, clinical trial design, computing power and sample size for correlated samples, and multiplicity adjustment for confidence intervals. He has over 100 publications in scientific journals and technical proceedings. Additionally, Dr. Efird serves as a Senior Consultant for The NCRR-funded RCMI Translational Research Network Data and Technology Coordinating Center.

Genetic epidemiology, cancer informatics, brain tumors, soft-tissue sarcomas, and HPV-related cancers. Additionally, he is founding co-chair for the advances in Bioinformatics and Genomics Symposium series. Dr. Efird has over 100 publications in scientific journals and proceedings.

Mong-Hong Lee is currently Professor in the Department of Molecular and Cellular Oncology of University of Texas MD Anderson Cancer Center and a faculty member at The University of Texas Graduate School of Biomedical Sciences at Houston (GSBS). In 1993, Dr. Lee received his Ph.D. degree in Molecular, Cellular, and Developmental Biology from the University of Pittsburgh, where he received the Stanton C. Crawford Award for teaching excellence. He then went on to complete a postdoctoral fellowship while serving as a research associate at Howard Hughes Medical Institute and Memorial Sloan-Kettering Cancer Center (1993-1997). After completing his fellowship, Dr. Lee came to M. D. Anderson in 1997 as an Assistant Professor (tenure track). He was promoted to his current position of Professor (tenured) in 2010. During his time at M. D. Anderson, Dr. Lee has been the principal investigator or a co-principal investigator for nine funded research projects. He also has been a grant reviewer for several funding agencies. Dr. Lee has been honored for his research activities, led by the Susan G. Komen Breast Cancer Foundation Research Award (2001), Fleming and Davenport Research Award (2001), and William G. McGowan Foundation Research Award (1998). In addition to research, for more than a decade, Dr. Lee has been a key contributor to the education of trainees at M. D. Anderson and the GSBS in a variety of ways. For example, at the GSBS, he has been the course coordinator for the Molecular Genetics of Human Cancer seminar since 2006 and an instructor for the Cancer Cell Signaling course since 2000. Dr. Lee has had a wealth of direct interaction with trainees throughout his career. Specifically, he has directly supervised 40 graduate students, 12 clinical residents and fellows, 12 undergraduate and Allied Health students, 9 postdoctoral research fellows, and 1 medical student. Furthermore, he has chaired or served on 71 examining committees, 67 advisory committees, and 39 supervisory committees. UT M. D. Anderson Cancer Center and the UT GSBS at Houston have well recognized Dr. Lee’s educational efforts. In 2009, he received the John P. McGovern Outstanding Teaching Award, which is given annually to a faculty member at M. D. Anderson and/or the GSBS. Most recently, he has recently been named the February 2010 Faculty Educator of the Month at MD Anderson Cancer Center. Also, he received the M. D. Anderson Outstanding Educator Award in 2003. Currently, Dr. Lee is an ad hoc reviewer for 25 journals. He also has been a guest editor for the journal Breast Diseases. Over the course of his career, Dr. Lee has authored more than 50 articles published in peer-reviewed journals, 4 book chapters, and 3 invited articles

Characterizing the roles of Cdk inhibitors (CKIs) in cancer formation, and exploiting signaling regulation in cancer therapy. Research projects focusing on: 1) roles of two CKI molecules that he cloned in tumorigenesis; 2) COP9 signalosome signaling regulation; 3) investigating the impact of hypoxia and PIm1 kinase in drug resistance; 4) employing Aurora B kinase inhibitor for cancer therapy; 5) p53-MDM2 signaling regulation and DNA damage; 6) Myc ubiquitination regulation; 7) Glycolysis and cancer metabolism.

Chulso Moon is having 1. Tenure Track Professorship in the Department of Oncology, Otolaryngology, Head and Neck Surgery, The Johns Hopkins University School of Medicine (2001-2007). 2. Principal Investigator, The Head and Neck Cancer Research Institute, The Johns Hopkins University School of Medicine (Director: Dr. David Sidransky) (2001-). 3. Attending physician, The Johns Hopkins Hospital (2001-2006). 4. Principal investigator, ONXY-015 cancer genetherapy program for advanced head/neck cancer (2001-2003). 5. Adjunct Professorship, Department of Otolaryngology and Head and Neck Surgery, The Johns Hopkins University school of Medicine (2008- Present). 6. Preceptor, Graduate Program in Human Genetics and Molecular Biology, The Johns Hopkins University school of Medicine (2005- Present, Thesis Advisor for Juna Lee, 2010 Ph.D. Candidate). 7. Director of Medical Oncology, Cleo Craig Memorial Cancer Clinic, The South-Western Medical Center, Lawton OK (2010-Present).

Cancer gene therapy

Dr. Notario’s expertise in Experimental Molecular Carcinogenesis has been recognized also through invitations to participate in U.S. and international scientific review and advisory committees, such as those for the U.S. National Institutes of Health, the American Association for Cancer Research, the U.S. Department of Defense, the Israel Science Foundation, the Italian National Center for Rare Diseases, the Italian Association for Research on Cancer, and the Department of Education and Science of Spain. In addition, Dr. Notario has been invited to act as an ad hoc expert reviewer for over 50 specialized U.S. national and international scientific journals. His service to Georgetown University included terms in the G.U.M.C. Research Committee and various faculty search committees, the Medical School Admissions Committee and the Lombardi Comprehensive Cancer Center Executive Committee, and is currently serving as Chairman of the Georgetown Institutional Biosafety Committee.

Biochemistry, Molecular Biology, Radiation Biology, Molecular Carcinogenesis and Tumor Biology.

Yuyan Wang received the B.S. of statistics in Beijing Normal University in 2013, and now she is getting her fifth year Ph.D. training in Peking Union Medical College in China, majoring in Biostatistics & Epidemiology. Her current research mainly focuses on cancer screening & imaging, clinical trials in cancer, oncogenomics, metabolomics & epigenetics of cancer. This time she will give us a decision analysis report about benefits and harms of low-dose CT screening, which aimed to evaluate population outcomes for lung cancer in urban areas of China. The findings favor conducting LDCT screening in urban China in terms of mortality outcome, and point out that approaches to reducing false diagnoses and optimizing other screening conditions are highly needed to maximize benefits and minimize harms associated with this screening device.

Biostatistics & Epidemiology

Tariq Completed his UG studies at University of Agriculture Faisalabad, where he was appointed as a coordinator of tutorial group, is currently working as Technical Product Support Manager & Demonstrator at Sure Bio Diagnostics & Pharmaceuticals - Pakistan and also pursuing his studies as Research Scholar at Center For Applied Molecular Biology. With the Tragic incidents of his relatives in his family he vowed to be a biology scientist and imparting role to find remedy against mysterious diseases especially conquesting cancer, genetic and infectious diseases by exploring molecular mechanisms and how our immune system adapts itself in fighting and exaggerating these diseases. Tariq organizes workshops on Biosafety, Biosecurity and Risk Assessment at life sciences departments of different universities. Demonstrate handling and technical aspects of scientific instruments used in molecular biology to university students. Monitors and facilitate students in their projects working at National Training and Research Laboratory.

Molecular Biology, Biomarkers